Key players in the microbiome therapeutics market are Seres Therapeutics, Enterome Bioscience, Rebiotix, Microbiome Therapeutics and Ritter Pharmaceuticals. The global microbiome therapeutics market is expected to grow from $0.
NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the 2022 Microbiome Therapeutics Global Market Report – https://www.reportlinker.com/p06320348/?utm_source=GNW
$29 billion in 2021 to $0.39 billion in 2022 at a compound annual growth rate (CAGR) of 34.7%. The microbiome therapeutics market is expected to reach US$1 billion by 2026 at a compound annual growth rate (CAGR) of 26.4%.
The microbiome therapeutics market consists of the sale by companies (organizations, sole traders, partnerships) of microbiome therapeutics and related services, which are used to treat and prevent various diseases. The microbiome includes the genetic material within a microbiota, which is a collection of microorganisms found in and on all multicellular organisms.
The main products of microbiome therapeutics are probiotics, prebiotics, symbiotics and other products. Probiotics are a combination of live, beneficial bacteria and/or yeast that live naturally in the body.
The various sales channels involved are hospital pharmacies, drugstores, retail pharmacies and e-commerce shops. The applications included are inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis and other applications.
The increasing prevalence of obesity is expected to drive the growth of the microbiome therapeutics market. A sedentary lifestyle, busy work life and unhealthy eating habits are gradually becoming the leading causes of obesity worldwide.
Increasing urbanization and busy lifestyles are leading to an increasing preference for packaged and processed foods and physical inactivity. Microbiome therapeutics help prevent and treat diabetes by regulating sugar levels.
For example, a survey in 2022 according to the UK Parliament found that men were more likely than women to be overweight or obese (68.2% of men, 60.4% of women). People aged 45 to 74 are most likely to be overweight or obese. Hence, the increasing prevalence of obesity is driving the growth of microbiome therapeutics.
Increased research and development is a key trend gaining popularity in the microbiome therapeutics market. Companies operating in the microbiome therapeutics market are focused on developing new innovations to increase their market share.
For example, Microbiotica, a UK-based company, raised $67 million in a Series B round in March 2022 to bring two microbiome-based lead assets through Phase 1b trials, set to begin this year .
In April 2022, Xbiome Inc, a China-based artificial intelligence microbiome therapeutics startup, acquired a clinical-stage M201 program from Assembly Biosciences, Inc for an undisclosed amount. This acquisition reflects Xbiome’s commitment as a leader in the emerging field of microbiome therapeutics.
Assembly Biosciences Inc is a US-based clinical-stage biotechnology company.
The countries covered in the Microbiome Therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the US.
Read the full report: https://www.reportlinker.com/p06320348/?utm_source=GNW
About report linker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research data you need—instantly and in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001